Table S2. Copy number alteration frequency in appendiceal adenocarcinoma, NET and GCC

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Gene | AC | NET | GCC | Gene | AC | NET | GCC |
| CNA | Total | CNArate (%) | CNA | Total | CNArate (%) | CNA | Total | CNArate (%) | CNA | Total | CNArate (%) | CNA | Total | CNArate (%) | CNA | Total | CNArate (%) |
| Amp-*MYC* | 10 | 415 | 2.4 | 0 | 11 | 0.0 | 0 | 52 | 0.0 | Amp-*AURKA* | 2 | 409 | 0.5 | 0 | 11 | 0.0 | 0 | 51 | 0.0 |
| Amp-*CCND1* | 9 | 415 | 2.2 | 0 | 11 | 0.0 | 0 | 52 | 0.0 | Amp-*CCND2* | 2 | 409 | 0.5 | 0 | 11 | 0.0 | 0 | 51 | 0.0 |
| Amp-*FGF19* | 7 | 401 | 1.7 | 0 | 11 | 0.0 | 0 | 50 | 0.0 | Amp-*EXT1* | 2 | 409 | 0.5 | 0 | 11 | 0.0 | 0 | 51 | 0.0 |
| Amp-*FGF4* | 6 | 409 | 1.5 | 0 | 11 | 0.0 | 0 | 52 | 0.0 | Amp-*HNRNPA2B1* | 2 | 409 | 0.5 | 0 | 11 | 0.0 | 0 | 51 | 0.0 |
| Amp-*FGF3* | 5 | 391 | 1.3 | 0 | 11 | 0.0 | 0 | 49 | 0.0 | Amp-*KDM5A* | 2 | 409 | 0.5 | 0 | 11 | 0.0 | 0 | 51 | 0.0 |
| Amp-*CDX2* | 4 | 408 | 1.0 | 0 | 11 | 0.0 | 0 | 51 | 0.0 | Amp-*CDK6* | 2 | 415 | 0.5 | 0 | 11 | 0.0 | 0 | 52 | 0.0 |
| Amp-*ERC1* | 4 | 409 | 1.0 | 0 | 11 | 0.0 | 0 | 51 | 0.0 | Amp-*FOXO1* | 1 | 396 | 0.3 | 0 | 11 | 0.0 | 0 | 49 | 0.0 |
| Amp-*MYB* | 4 | 409 | 1.0 | 0 | 11 | 0.0 | 0 | 51 | 0.0 | Amp-*H3F3A* | 1 | 408 | 0.2 | 0 | 11 | 0.0 | 0 | 51 | 0.0 |
| Amp-*SS18* | 3 | 408 | 0.7 | 0 | 11 | 0.0 | 0 | 51 | 0.0 | Amp-*FGF23* | 1 | 409 | 0.2 | 0 | 11 | 0.0 | 1 | 51 | 2.0 |
| Amp-*FLT3* | 3 | 409 | 0.7 | 0 | 11 | 0.0 | 0 | 51 | 0.0 | Amp-*MDM2* | 1 | 415 | 0.2 | 0 | 11 | 0.0 | 2 | 52 | 3.8 |
| Amp-*HSP90AB1* | 3 | 409 | 0.7 | 0 | 11 | 0.0 | 0 | 51 | 0.0 | Amp-*FUS* | 0 | 404 | 0.0 | 0 | 11 | 0.0 | 1 | 50 | 2.0 |
| Amp-*GNAS* | 2 | 408 | 0.5 | 0 | 11 | 0.0 | 0 | 51 | 0.0 | Amp-*SF3B1* | 0 | 407 | 0.0 | 0 | 11 | 0.0 | 1 | 51 | 2.0 |

AC, adenocarcinoma; Amp, amplification; CNA, copy number alteration; GCC, goblet cell carcinoid; NET, neuroendocrine tumor.